Monitoring HIV treatment in developing countries

doi:10.1136/bmj.332.7541.602

Review

. 2006 Mar 11;332(7541):602-4.

doi: 10.1136/bmj.332.7541.602.

Monitoring HIV treatment in developing countries

Serena P Koenig¹, Daniel R Kuritzkes, Martin S Hirsch, Fernet Léandre, Joia S Mukherjee, Paul E Farmer, Carlos del Rio

Affiliations

PMID: 16528087
PMCID: PMC1397781
DOI: 10.1136/bmj.332.7541.602

Review

Monitoring HIV treatment in developing countries

Serena P Koenig et al. BMJ. 2006.

. 2006 Mar 11;332(7541):602-4.

doi: 10.1136/bmj.332.7541.602.

Authors

Serena P Koenig¹, Daniel R Kuritzkes, Martin S Hirsch, Fernet Léandre, Joia S Mukherjee, Paul E Farmer, Carlos del Rio

Affiliation

¹ Division of Social Medicine and Health Inequalities, Brigham and Women's Hospital, 1620 Tremont Street, Boston, MA 02120, USA.

PMID: 16528087
PMCID: PMC1397781
DOI: 10.1136/bmj.332.7541.602

Abstract

Laboratory monitoring of antiretroviral therapy helps limit resistance but is currently not feasible in developing countries. Alternative short term approaches are needed

PubMed Disclaimer

Figures

**Figure 1**
Waiting for HIV drugs in Port-au-Prince Credit: AP PHOTO/ARIANA CUBILLAS

See this image and copyright information in PMC

Cited by

Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial.
Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, Downing R, Coutinho A, Solberg P, Alexander LN, Tappero J, Campbell J, Moore DM. Mermin J, et al. BMJ. 2011 Nov 9;343:d6792. doi: 10.1136/bmj.d6792. BMJ. 2011. PMID: 22074711 Free PMC article. Clinical Trial.
Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand.
Jourdain G, Le Cœur S, Ngo-Giang-Huong N, Traisathit P, Cressey TR, Fregonese F, Leurent B, Collins IJ, Techapornroong M, Banchongkit S, Buranabanjasatean S, Halue G, Nilmanat A, Luekamlung N, Klinbuayaem V, Chutanunta A, Kantipong P, Bowonwatanuwong C, Lertkoonalak R, Leenasirimakul P, Tansuphasawasdikul S, Sang-A-Gad P, Pathipvanich P, Thongbuaban S, Wittayapraparat P, Eiamsirikit N, Buranawanitchakorn Y, Yutthakasemsunt N, Winiyakul N, Decker L, Barbier S, Koetsawang S, Sirirungsi W, McIntosh K, Thanprasertsuk S, Lallemant M; PHPT-3 study team. Jourdain G, et al. PLoS Med. 2013 Aug;10(8):e1001494. doi: 10.1371/journal.pmed.1001494. Epub 2013 Aug 6. PLoS Med. 2013. PMID: 23940461 Free PMC article. Clinical Trial.
Universal HIV testing and treatment and HIV stigma reduction: a comparative thematic analysis of qualitative data from the HPTN 071 (PopART) trial in South Africa and Zambia.
Viljoen L, Bond VA, Reynolds LJ, Mubekapi-Musadaidzwa C, Baloyi D, Ndubani R, Stangl A, Seeley J, Pliakas T, Bock P, Fidler S, Hayes R, Ayles H, Hargreaves JR, Hoddinott G; HPTN 071 (PopART) study team. Viljoen L, et al. Sociol Health Illn. 2021 Jan;43(1):167-185. doi: 10.1111/1467-9566.13208. Epub 2020 Oct 21. Sociol Health Illn. 2021. PMID: 33085116 Free PMC article. Clinical Trial.
Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings.
Calmy A, Balestre E, Bonnet F, Boulle A, Sprinz E, Wood R, Delaporte E, Messou E, McIntyre J, El Filali KM, Schechter M, Kumarasamy N, Bangsberg D, McPhail P, Van Der Borght S, Zala C, Egger M, Thiébaut R, Dabis F; T-LINC of IeDEA Collaboration (Asia, South America, East, Southern and West Africa). Calmy A, et al. BMC Infect Dis. 2012 Jun 28;12:147. doi: 10.1186/1471-2334-12-147. BMC Infect Dis. 2012. PMID: 22742573 Free PMC article.
HIV/AIDS-Related Knowledge and Attitudes Among Chinese College Students and Associated Factors: A Cross-Sectional Study.
Zhang L, Yu H, Luo H, Rong W, Meng X, Du X, Tan X. Zhang L, et al. Front Public Health. 2022 Jan 12;9:804626. doi: 10.3389/fpubh.2021.804626. eCollection 2021. Front Public Health. 2022. PMID: 35096751 Free PMC article.

See all "Cited by" articles

References

1. Detels RMA, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280: 1497-503. - PubMed
1. CASCADE (Concerted Action on Seroconversion to AIDS and Death in Europe) Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000;355: 1158-9. - PubMed
1. World Health Organization. “3×5” progress report. Geneva: WHO, 2004.
1. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public heath approach. Geneva: WHO, 2004. www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf (accessed 13 Feb 2005).
1. Behforouz HL, Farmer PE, Mukherjee JS. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 2004;38(suppl 5): S429-36. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

K24 RR16482/RR/NCRR NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Detels RMA, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280: 1497-503. - PubMed

[2] Detels RMA, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280: 1497-503. - PubMed

[3] CASCADE (Concerted Action on Seroconversion to AIDS and Death in Europe) Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000;355: 1158-9. - PubMed

[4] CASCADE (Concerted Action on Seroconversion to AIDS and Death in Europe) Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000;355: 1158-9. - PubMed

[5] World Health Organization. “3×5” progress report. Geneva: WHO, 2004.

[6] World Health Organization. “3×5” progress report. Geneva: WHO, 2004.

[7] World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public heath approach. Geneva: WHO, 2004. www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf (accessed 13 Feb 2005).

[8] World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public heath approach. Geneva: WHO, 2004. www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf (accessed 13 Feb 2005).

[9] Behforouz HL, Farmer PE, Mukherjee JS. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 2004;38(suppl 5): S429-36. - PubMed

[10] Behforouz HL, Farmer PE, Mukherjee JS. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 2004;38(suppl 5): S429-36. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Monitoring HIV treatment in developing countries

Affiliation

Monitoring HIV treatment in developing countries

Authors

Affiliation

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical